Timolol Maleate
Sponsors
Beacon Therapeutics (USA) Inc., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pharmaceutical Research Network, Vistakon Pharmaceuticals, Santen Oy
Conditions
Anterior Ischemic Optic NeuropathyCapsule OpacificationChronic WoundsEsophageal and Gastric VaricesExfoliation SyndromeGlaucoma, Open-AngleGlaucoma, PigmentaryGlaucoma; Drugs
Phase 1
Phase 2
BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension
CompletedNCT01707381
Start: 2012-11-30End: 2014-02-28Updated: 2018-09-04
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
CompletedNCT04830397
Start: 2021-03-31End: 2022-02-17Updated: 2025-01-17
Phase 3
Prevention of Esophageal Varices by Beta-Adrenergic Blockers
CompletedNCT00006398
Start: 1993-08-31End: 2002-09-30Updated: 2017-06-01
A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa
WithdrawnCTIS2024-511181-36-00
Target: 5Updated: 2024-09-17
Phase 4
Unknown Phase
A Comfort Survey of Open-angle Glaucoma or Ocular Hypertension Patients Treated With 2 Drugs
CompletedNCT00823043
Start: 2009-01-31End: 2009-07-31Updated: 2015-03-06
Absorption and Safety of Topical Timolol to Treat Chronic Wounds
CompletedNCT04903366
Start: 2017-11-21End: 2020-01-14Updated: 2021-05-27
Prophylactic Use of Timolol Maleate to Prevent Intraocular Pressure Elevation After Nd:YAG Laser Posterior Capsulotomy
CompletedNCT07729189
Start: 2025-03-10End: 2025-09-10Updated: 2026-07-27